Oragenics Announces Closing of $6.5 Million Registered Direct Offering
December 29 2020 - 4:00PM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”) a company focused on the creation of the Terra CoV-2
vaccine candidate to combat the novel coronavirus pandemic, today
announced the closing of its previously announced registered direct
offering of 14,444,444 shares of common stock at a purchase price
of $0.45 per share.
A.G.P./Alliance Global Partners acted as the placement agent for
the offering.
The gross proceeds from this offering were $6.5 million before
deducting the placement agent’s fees and other offering expenses
payable by the Company. The Company intends to use the net proceeds
of the offering primarily to continue funding our pre-clinical
development of our SARS-CoV-2 vaccine, Terra CoV-2 and our
lantibiotics program and for general corporate purposes, including
research and development activities, capital expenditures and
working capital.
The shares of common stock were offered by the Company pursuant
to a "shelf" registration statement on Form S-3 (File No.
333-235763) previously filed with the Securities and Exchange
Commission (the “SEC”) and declared effective by the SEC on January
13, 2020. The offering was made only by means of a prospectus,
including a prospectus supplement, forming a part of the effective
registration statement. A final prospectus supplement and
accompanying prospectus relating to the shares of common stock
offered was filed with the SEC on December 28, 2020 and is
available on the SEC’s website at www.sec.gov. Electronic copies of
the prospectus supplement may be obtained from A.G.P./Alliance
Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022
or via telephone at 212-624-2060 or email:
prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the Company’s securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Oragenics, Inc.
Oragenics, Inc. is focused on the creation of the Terra CoV-2
vaccine candidate to combat the novel coronavirus pandemic and the
further development of effective treatments for novel antibiotics
against infectious disease. The Company is dedicated to the
development and commercialization of a vaccine candidate providing
specific immunity from novel coronavirus. The Terra CoV-2
immunization leverages coronavirus spike protein research conducted
by the National Institute of Health. In addition, Oragenics has an
exclusive worldwide channel collaboration with ILH Holdings, Inc.
(n/k/a Eleszto Genetika, Inc.), relating to the development of
novel lantibiotics.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include statements about the
intended use of net proceeds from the registered direct offering.
These and other forward-looking statements are predictions and
projections about future events and trends based on our current
expectations, objectives and intentions and premised on current
assumptions. Actual results could be materially different than
those expressed, implied, or anticipated by forward-looking
statements due to a variety of factors, including, but not limited
to those discussed under the caption entitled “Risk Factors” in our
Annual Report on Form 10-K, as updated by our Form 8-K filed on May
8, 2020, and subsequent filings on Form 10-Q or 8-K with the U.S.
Securities and Exchange Commission. All information set forth in
this press release is as of the date hereof. You should consider
these factors in evaluating the forward-looking statements included
in this press release and not place undue reliance on such
statements. We do not assume any obligation to publicly provide
revisions or updates to any forward-looking statements, whether as
a result of new information, future developments or otherwise,
should circumstances change, except as otherwise required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201229005426/en/
Oragenics, Inc. Corporate: Michael Sullivan, 813-286-7900 Chief
Financial Officer msullivan@oragenics.com
or
Investors: John Marco Managing Director CORE IR
516-222-2560 johnm@coreir.com
Media: Jules Abraham CORE IR 917-885-7378
julesa@coreir.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024